Menu
/REGISTER
PPB
Fielding
Montecito
Powershare
Loading...
You are here:  Home  >  Health Care  -  Page 31

Santa Barbara Web Design
Latest

Europeans recommend approval of Amgen’s biosimilar of AbbVie’s Humira

By   /  Friday, January 27th, 2017  /  Health Care, Latest news, Technology  /  Comments Off on Europeans recommend approval of Amgen’s biosimilar of AbbVie’s Humira

The European Medicines Agency recommended the approval of the ABP 501, a biosimilar of AbbVie’s Humira (adalimumab), for treatment of inflammatory diseases, Thousand Oaks-based biotech company Amgen announced on Jan. 27. The EMA recommended ABP 501’s use for moderate-to-severe rheumatoid arthritis, psoriatic arthritis, severe ankylosing spondylitis, severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe Read More →

Read More →
Latest

Cynvenio inks deal with Milenia Labs to distribute blood test

By   /  Friday, January 27th, 2017  /  Health Care, Latest news, Technology  /  Comments Off on Cynvenio inks deal with Milenia Labs to distribute blood test

Westlake Village cancer treatment company Cynvenio Biosystems announced an exclusive agreement with diagnostic test company Milenia Labs to distribute a blood test for breast cancer at its 12 diagnostic centers in Mexico. Financial details of the deal were not disclosed. The test provides real-time information about cancer cell activity for patients who have completed treatment Read More →

Read More →
Latest

Patent ruling in favor of Amgen has shares skyrocketing

By   /  Friday, January 13th, 2017  /  Health Care, Latest news, Tri-County Public Companies  /  Comments Off on Patent ruling in favor of Amgen has shares skyrocketing

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Diagnosis bleak if Affordable Care Act repealed

By   /  Friday, January 13th, 2017  /  Health Care, Latest news, Tri-County Economy  /  Comments Off on Diagnosis bleak if Affordable Care Act repealed

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Tri-county hospitals expanding facilities

By   /  Friday, January 13th, 2017  /  Health Care, Top Stories, Top Story  /  Comments Off on Tri-county hospitals expanding facilities

Santa Barbara Cottage Hospital is expanding to more than 700,000 square feet and making seismic improvements. (Nik Blaskovich)

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen updates agreement with DaVita for dialysis treatment

By   /  Monday, January 9th, 2017  /  Health Care, Latest news, Tri-County Public Companies  /  Comments Off on Amgen updates agreement with DaVita for dialysis treatment

Thousand Oaks biotech company Amgen entered into a six-year supply agreement with DaVita for dialysis treatments, the company announced on Jan. 9. Under the terms of the new agreement, Amgen will supply DaVita with Epogen and Aranesp for agents to stimulate red blood cells in dialysis treatment in the United States and Puerto Rico. The Read More →

Read More →
Latest

Amgen partners with Immatics Biotechnologies to develop cancer drugs

By   /  Monday, January 9th, 2017  /  Health Care, Latest news, Tri-County Public Companies  /  Comments Off on Amgen partners with Immatics Biotechnologies to develop cancer drugs

Thousand Oaks biotech company Amgen formed a potential $500 million partnership with Immatics Biotechnologies GmbH to research and develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers, the company announced on Jan. 9. Under the terms of the agreement, Immatics will receive $30 million upfront and can receive more than $500 million in development, regulatory Read More →

Read More →